Shots:
The Fourth quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. Starting with the latest acquisitions, BMS acquired Mirati Therapeutics for ~$5.8B and AbbVie acquired ImmunoGen for $10.1BÂ Â Â
The Fourth quarter of the year also showcases multiple clinical trial results from Regeneron’s Two-Year…
